T1	PROC 46 80	Evaluación de eficacia y seguridad
T2	ANAT 88 135	células madre mesenquimales de cordón umbilical
#1	AnnotatorNotes T2	C2826385; Umbilical Cord Blood-Derived Mesenchymal Stem Cells; Cell
T3	PROC 896 905	PaO2/FiO2
#2	AnnotatorNotes T3	C3897988; Partial Pressure Arterial Oxygen to Fraction Inspired Oxygen Ratio Measurement; Laboratory Procedure
T4	PROC 144 155	tratamiento
#3	AnnotatorNotes T4	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T5	DISO 173 215	insuficiencia respiratoria por coronavirus
T6	PROC 238 379	Ensayo clínico piloto anidado en un estudio observacional de cohorte prospectivo, doble ciego, randomizado, paralelo y controlado con placebo
T7	CHEM 442 445	MSC
#4	AnnotatorNotes T7	C1720705; Human mesenchymal stem cell-containing product; Immunologic Factor · Pharmacologic Substance
T8	PROC 388 425	evaluación de la eficacia y seguridad
T9	DISO 466 504	síndrome de distrés respiratorio agudo
#5	AnnotatorNotes T9	C5397144; Acute respiratory distress syndrome due to COVID-19; Disease or Syndrome
T10	DISO 518 540	infección por COVID-19
#6	AnnotatorNotes T10	C5203670; COVID19 (disease); Disease or Syndrome
T11	DISO 564 593	Dificultad respiratoria aguda
#7	AnnotatorNotes T11	C0264490; Acute respiratory failure; Disease or Syndrome
T12	DISO 620 658	Síndrome de distrés respiratorio agudo
#8	AnnotatorNotes T12	C0035222; Respiratory Distress Syndrome, Adult; Disease or Syndrome | C0748355; Acute respiratory distress; Disease or Syndrome
T13	PROC 708 756	estudio epidemiológico observacional prospectivo
T14	PROC 804 818	ingreso en UCI
T15	DISO 823 849	Distrés respiratorio agudo
T16	PROC 1123 1134	Tratamiento
#9	AnnotatorNotes T16	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T17	CHEM 1139 1164	fármacos inmunosupresores
#10	AnnotatorNotes T17	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
T18	CHEM 1166 1177	tocilizumab
#11	AnnotatorNotes T18	C1609165; tocilizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T19	CHEM 1213 1229	corticosteroides
#12	AnnotatorNotes T19	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T20	DISO 1233 1254	Enfermedad neoplásica
#13	AnnotatorNotes T20	C0006826; Malignant Neoplasms; Neoplastic Process | C0027651; Neoplasms; Neoplastic Process | C1882062; Neoplastic disease; Neoplastic Process
T21	DISO 1300 1316	inmunodeprimidos
#14	AnnotatorNotes T21	C0085393; Immunocompromised Host; Finding
T22	PROC 1326 1353	tratamiento con corticoides
T23	DISO 1362 1382	distrés respiratorio
#15	AnnotatorNotes T23	C0035222; Respiratory Distress Syndrome, Adult; Disease or Syndrome | C0748355; Acute respiratory distress; Disease or Syndrome
T24	PROC 1444 1459	estudio clínico
#16	AnnotatorNotes T24	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T25	CHEM 1467 1487	fármaco experimental
#17	AnnotatorNotes T25	C0304229; Experimental drug; Pharmacologic Substance
T26	PROC 974 998	consentimiento informado
#18	AnnotatorNotes T26	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T27	CHEM 1179 1188	sarilumab
#19	AnnotatorNotes T27	C3885145; sarilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T28	PROC 774 793	PCR para SARS-CoV-2
#20	AnnotatorNotes T28	C5244035; SARS-CoV-2 PCR test; Laboratory Procedure | C5541700; PCR for SARS-CoV-2; Laboratory Procedure
T29	CHEM 1342 1353	corticoides
#21	AnnotatorNotes T29	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T30	DISO 1520 1530	patologías
#22	AnnotatorNotes T30	C0677042; Pathology processes; Pathologic Function
T31	Date 13 17	2020
T32	LIVB 159 168	pacientes
#23	AnnotatorNotes T32	C0030705; Patients; Patient or Disabled Group
T33	LIVB 204 215	coronavirus
#24	AnnotatorNotes T33	C5203676; SARS-CoV-2; Virus
T34	LIVB 299 306	cohorte
#25	AnnotatorNotes T34	C0599755; Cohort; Population Group
T35	Dose 429 438	dos dosis
T36	LIVB 452 461	pacientes
#26	AnnotatorNotes T36	C0030705; Patients; Patient or Disabled Group
T37	LIVB 783 793	SARS-CoV-2
#27	AnnotatorNotes T37	C5203676; SARS-CoV-2; Virus
T38	LIVB 923 931	Paciente
#28	AnnotatorNotes T38	C0030705; Patients; Patient or Disabled Group
T39	Age 932 947	de 18 a 70 años
T40	LIVB 1013 1021	paciente
#29	AnnotatorNotes T40	C0030705; Patients; Patient or Disabled Group
T41	LIVB 1031 1044	representante
#30	AnnotatorNotes T41	C0030701; Patient Representatives; Professional or Occupational Group | C0600419; Patient Agent; Group | C1998038; Patient advocate (person); Population Group (?)
T43	Neg_cue 1318 1325	excepto
T44	LIVB 1387 1406	Mujeres embarazadas
#31	AnnotatorNotes T44	C0033011; Pregnant Women; Population Group
T45	LIVB 1409 1418	lactantes
#32	AnnotatorNotes T45	C4316174; Patients who are breastfeeding; Patient or Disabled Group
T46	Duration 1491 1510	los últimos 30 días
T48	ANAT 187 199	respiratoria
#33	AnnotatorNotes T48	C0035237; Respiratory System; Body System | C1269561; Entire respiratory system; Body System
T49	PHYS 486 498	respiratorio
#34	AnnotatorNotes T49	C0035203; Respiration; Physiologic Function
T50	PHYS 575 587	respiratoria
#35	AnnotatorNotes T50	C0035203; Respiration; Physiologic Function
T51	PHYS 640 652	respiratorio
#36	AnnotatorNotes T51	C0035203; Respiration; Physiologic Function
T52	PHYS 831 843	respiratorio
#37	AnnotatorNotes T52	C0035203; Respiration; Physiologic Function
T53	LIVB 1290 1299	Pacientes
#38	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	PHYS 1370 1382	respiratorio
#39	AnnotatorNotes T54	C0035203; Respiration; Physiologic Function
T47	Duration 1104 1119	menor de 3 días
T42	PHYS 1395 1406	embarazadas
#40	AnnotatorNotes T42	C0032961; Pregnancy; Organism Function
T55	CHEM 88 115	células madre mesenquimales
#41	AnnotatorNotes T55	C1720705; Human mesenchymal stem cell-containing product; Immunologic Factor · Pharmacologic Substance
T56	LIVB 949 960	ambos sexos
#42	AnnotatorNotes T56	C0025266; Male population group; Population Group + C0043210; Woman; Population Group
A1	Assertion T22 Negated
A2	Status T24 History_of
A3	Status T25 History_of
#43	AnnotatorNotes T1	C0511730; Identify product efficacy and safety issues; Health Care Activity
#44	AnnotatorNotes T8	C0511730; Identify product efficacy and safety issues; Health Care Activity
#45	AnnotatorNotes T14	C5419131; Intensive Care Unit Stay; Health Care Activity
#46	AnnotatorNotes T15	C0035222; Respiratory Distress Syndrome, Adult; Disease or Syndrome | C0748355; Acute respiratory distress; Disease or Syndrome
T57	Observation 1268 1285	remisión completa
A4	Assertion T57 Negated
#47	AnnotatorNotes T57	C0677874; In complete remission; Finding
T58	Neg_cue 1264 1267	sin
T59	Observation 1573 1600	participación en el estudio
A5	Assertion T59 Contraindicated
#48	AnnotatorNotes T59	C1278516; Patient participation status; Finding (?)
R1	Before Arg1:T30 Arg2:T59	
T60	CONC 1081 1103	Supervivencia esperada
#49	AnnotatorNotes T60	C0023671; Life Expectancy; Group Attribute (?)
R2	Has_Duration_or_Interval Arg1:T60 Arg2:T47	
R4	Experiences Arg1:T32 Arg2:T4	
R5	Causes Arg1:T33 Arg2:T5	
R6	Location_of Arg1:T48 Arg2:T5	
#50	AnnotatorNotes T5	C5397144; Acute respiratory distress syndrome due to COVID-19; Disease or Syndrome (?)
R7	Experiences Arg1:T34 Arg2:T7	
R8	Experiences Arg1:T34 Arg2:T9	
R9	Experiences Arg1:T34 Arg2:T10	
R10	Causes Arg1:T10 Arg2:T9	
R11	Experiences Arg1:T36 Arg2:T7	
R12	Experiences Arg1:T36 Arg2:T9	
R13	Experiences Arg1:T36 Arg2:T10	
R15	Experiences Arg1:T36 Arg2:T49	
R16	Has_Dose_or_Strength Arg1:T7 Arg2:T35	
T61	Result_or_Value 794 802	positivo
#51	AnnotatorNotes T61	C1446409; Positive; Finding
R20	Has_Result_or_Value Arg1:T28 Arg2:T61	
R21	Causes Arg1:T37 Arg2:T61	
T62	Result_or_Value 885 895	100 mmHg <
R23	Has_Result_or_Value Arg1:T3 Arg2:T62	
T63	Result_or_Value 906 916	≥ 200 mmHg
R24	Has_Result_or_Value Arg1:T3 Arg2:T63	
T64	Quantifier_or_Qualifier 850 858	moderado
#52	AnnotatorNotes T64	C0205081; Moderate (severity modifier); Qualitative Concept
R25	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T64	
T65	CONC 860 880	definición de Berlín
#53	AnnotatorNotes T65	C5420236; Berlin Criteria for Acute Respiratory Distress Syndrome; Intellectual Product
R27	Has_Age Arg1:T38 Arg2:T39	
R28	Has_Age Arg1:T56 Arg2:T39	
R29	Negation Arg1:T58 Arg2:T57	
R30	Before Arg1:T20 Arg2:T57	
T66	Quantifier_or_Qualifier 1255 1261	activa
#54	AnnotatorNotes T66	C0679217; Active State; Idea or Concept
R31	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T66	
R32	Used_for Arg1:T17 Arg2:T16	
R33	Used_for Arg1:T18 Arg2:T16	
R34	Used_for Arg1:T27 Arg2:T16	
T67	Quantifier_or_Qualifier 1198 1208	permitidos
R35	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T67	
R36	Used_for Arg1:T19 Arg2:T16	
R37	Experiences Arg1:T53 Arg2:T21	
R38	Experiences Arg1:T53 Arg2:T23	
R40	Experiences Arg1:T53 Arg2:T54	
R41	Negation Arg1:T43 Arg2:T22	
R42	Used_for Arg1:T29 Arg2:T22	
A6	Assertion T29 Negated
R43	Negation Arg1:T43 Arg2:T29	
R44	Experiences Arg1:T44 Arg2:T42	
T68	Observation 1422 1459	Participación en otro estudio clínico
A7	Status T68 History_of
R45	Used_for Arg1:T25 Arg2:T24	
R46	Overlap Arg1:T24 Arg2:T46	
R47	Overlap Arg1:T68 Arg2:T46	
T69	Quantifier_or_Qualifier 1514 1519	Otras
#55	AnnotatorNotes T69	C0205394; Other; Qualitative Concept
R48	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T69	
R49	Experiences Arg1:T32 Arg2:T5	
R50	Overlap Arg1:T21 Arg2:T23	
R3	Used_for Arg1:T55 Arg2:T4	
R14	Overlap Arg1:T25 Arg2:T46	
R17	Experiences Arg1:T53 Arg2:T22	
#56	AnnotatorNotes T22	C0149783; Steroid therapy; Therapeutic or Preventive Procedure
A8	Experiencer T45 Patient
A9	Experiencer T44 Patient
A10	Experiencer T53 Patient
A11	Experiencer T32 Patient
A12	Experiencer T34 Patient
A13	Experiencer T36 Patient
A14	Experiencer T38 Patient
A15	Experiencer T56 Patient
A16	Experiencer T40 Patient
A17	Experiencer T41 Other
